NASDAQ:MTEM - Molecular Templates Stock Price, Forecast & News

Molecular Templates trades on the NASDAQ under the ticker symbol "MTEM."

Molecular Templates shares reverse split on Wednesday, August 2nd 2017. The 1-11 reverse split was announced on Tuesday, August 1st 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, August 1st 2017. An investor that had 100 shares of Molecular Templates stock prior to the reverse split would have 9 shares after the split.

Molecular Templates Inc (NASDAQ:MTEM) announced its quarterly earnings data on Monday, August, 12th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.23) by $0.02. The biotechnology company earned $5.45 million during the quarter, compared to the consensus estimate of $6 million. Molecular Templates had a negative net margin of 289.90% and a negative return on equity of 44.86%. View Molecular Templates' Earnings History.

Molecular Templates is scheduled to release their next quarterly earnings announcement on Thursday, March 26th 2020. View Earnings Estimates for Molecular Templates.

2 Wall Street analysts have issued 12 month target prices for Molecular Templates' stock. Their forecasts range from $12.00 to $12.00. On average, they anticipate Molecular Templates' stock price to reach $12.00 in the next twelve months. This suggests that the stock has a possible downside of 17.0%. View Analyst Price Targets for Molecular Templates.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Molecular Templates in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Molecular Templates.

News stories about MTEM stock have trended neutral on Tuesday, InfoTrie Sentiment reports. The research group ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Molecular Templates earned a media sentiment score of 0.4 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Molecular Templates.

Molecular Templates saw a increase in short interest during the month of January. As of January 15th, there was short interest totalling 1,260,000 shares, an increase of 10.5% from the December 31st total of 1,140,000 shares. Based on an average daily trading volume, of 348,800 shares, the short-interest ratio is presently 3.6 days. Approximately 5.7% of the shares of the company are sold short. View Molecular Templates' Current Options Chain.

Some companies that are related to Molecular Templates include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Molecular Templates investors own include ZIOPHARM Oncology (ZIOP), Novavax (NVAX), Synergy Pharmaceuticals (SGYP), TG Therapeutics (TGTX), Alibaba Group (BABA), Amarin (AMRN), Corbus Pharmaceuticals (CRBP), Gilead Sciences (GILD), SLS International (SLS) and Inovio Pharmaceuticals (INO).

Molecular Templates' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BVF Inc. IL (9.08%), Perceptive Advisors LLC (6.69%), FMR LLC (1.31%), Sectoral Asset Management Inc (1.17%), Parkman Healthcare Partners LLC (0.92%) and State Street Corp (0.72%). Company insiders that own Molecular Templates stock include Associates LLC Cdk, David Hirsch, Longitude Capital Partners Iii and Scott D Morenstein. View Institutional Ownership Trends for Molecular Templates.

MTEM stock was sold by a variety of institutional investors in the last quarter, including AXA, BVF Inc. IL, Goldman Sachs Group Inc., UBS Group AG and Bank of America Corp DE. View Insider Buying and Selling for Molecular Templates.

MTEM stock was bought by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, FMR LLC, Parkman Healthcare Partners LLC, Monashee Investment Management LLC, Abingworth LLP, Sectoral Asset Management Inc, Man Group plc and EAM Investors LLC. Company insiders that have bought Molecular Templates stock in the last two years include Associates LLC Cdk, David Hirsch, Longitude Capital Partners Iii and Scott D Morenstein. View Insider Buying and Selling for Molecular Templates.

Shares of MTEM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MTEM stock can currently be purchased for approximately $14.45.

Molecular Templates has a market capitalization of $534.22 million and generates $13.28 million in revenue each year. The biotechnology company earns $-30,290,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis. Molecular Templates employs 68 workers across the globe.View Additional Information About Molecular Templates.

The official website for Molecular Templates is http://www.mtem.com/.

Molecular Templates' mailing address is 9301 AMBERGLEN BLVD. SUITE 100, AUSTIN TX, 78729. The biotechnology company can be reached via phone at 512-869-1555 or via email at [email protected]